Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 16.

Scherrer, A U. Epidemiology and clinical impact of HIV-1 drug resistance. 2018, University of Zurich, Faculty of Medicine.

Sekaggya-Wiltshire, C; von Braun, A; Scherrer, A U; Manabe, Y C; Buzibye, A; Muller, D; Ledergerber, B; Gutteck, U; Corti, N; Kambugu, A; Byakika-Kibwika, P; Lamorde, M; Castelnuovo, B; Fehr, J; Kamya, M R (2017). Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients. Journal of Antimicrobial Chemotherapy, 72(4):1172-1177.

Combes, J D; Clifford, G M; Egger, M; Cavassini, M; Hirsch, H; Hauser, C; Calmy, A; Schmid, P; Bernasconi, E; Gunthard, H F; Franceschi, S; Waterboer, T; Scherrer, A U (2016). Human papillomavirus antibody response following highly active antiretroviral therapy initiation among men who have sex with men. AIDS, 31(4):561-569.

Metzner, K J; Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Aubert, V; Furrer, H; Hirsch, H; Vernazza, P L; Cavassini, M; Calmy, A; Bernasconi, E; Weber, R; Gunthard, H F (2014). Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. AIDS, 28(15):2231-2239.

Kohler, Ines; Scherrer, A U; Zagordi, O; Bianchi, M; Wyrzucki, A; Steck, M; Ledergerber, B; Gunthard, H F; Hangartner, L (2014). Prevalence and predictors for homo- and heterosubtypic antibodies against influenza a virus. Clinical Infectious Diseases, 59(10):1386-1393.

Schüpbach, J; Gebhardt, M D; Scherrer, A U; Bisset, L R; Niederhauser, C; Regenass, S; Yerly, S; Aubert, V; Suter, F; Pfister, S; Martinetti, G; Andreutti, C; Klimkait, T; Brandenberger, M; Gunthard, H F (2013). Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns. PLoS ONE, 8(8):e71662.

Schüpbach, J; Bisset, L R; Gebhardt, M D; Regenass, S; Bürgisser, P; Gorgievski, M; Klimkait, T; Andreutti, C; Martinetti, G; Niederhauser, C; Yerly, S; Pfister, S; Schultze, D; Brandenberger, M; Schöni-Affolter, F; Scherrer, A U; Gunthard, H F (2012). Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection. BMC Infectious Diseases, 12(88):1471-2334.

Scherrer, A U; von Wyl, V; Götte, M; Klimkait, T; Cellerai, C; Yerly, S; Böni, J; Held, L; Ledergerber, B; Günthard, H F (2012). Polymorphic mutations associated with the emergence of the multi-nucleoside/tide resistance mutations 69 insertion and Q151M. Journal of Acquired Immune Deficiency Syndromes, 59(2):105-112.

Rieder, P; Joos, B; Scherrer, A U; Kuster, H; Braun, D; Grube, C; Niederöst, B; Leemann, C; Gianella, S; Metzner, K J; Böni, J; Weber, R; Günthard, H F (2011). Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection. Clinical Infectious Diseases, 53(12):1271-1279.

Scherrer, A U; Ledergerber, B; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Rauch, A; Hirschel, B; Cavassini, M; Elzi, L; Vernazza, P L; Bernasconi, E; Held, L; Günthard, H F (2011). Improved virological outcome in white patients infected with HIV-1 non-B subtypes compared to subtype B. Clinical Infectious Diseases, 53(11):1143-1152.

Scherrer, A U; von Wyl, V; Joos, B; Klimkait, T; Bürgisser, P; Yerly, S; Böni, J; Ledergerber, B; Günthard, H F (2011). Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study. Journal of Infectious Diseases, 203(6):791-797.

Metzner, K J; Leemann, C; Di Giallonardo, F; Grube, C; Scherrer, A U; Braun, D; Kuster, H; Weber, R; Guenthard, H F (2011). Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. PLoS ONE, 6(7):e21734.

Scherrer, A U; von Wyl, V; Böni, J; Yerly, S; Klimkait, T; Bürgisser, P; Garzoni, C; Hirschel, B; Cavassini, M; Battegay, M; Vernazza, P L; Bernasconi, E; Ledergerber, B; Günthard, H F (2011). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. JAIDS Journal of Acquired Immune Deficiency Syndromes, 57(1):24-31.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Schmid, A; Gianella, S; von Wyl, V; Metzner, K J; Scherrer, A U; Niederöst, B; Althaus, C F; Rieder, P; Grube, C; Joos, B; Weber, R; Fischer, M; Günthard, H F (2010). Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS ONE, 5(10):e13310.

Scherrer, A U; Hasse, B; von Wyl, V; Yerly, S; Böni, J; Bürgisser, P; Klimkait, T; Bucher, H C; Ledergerber, B; Günthard, H F (2009). Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). HIV Medicine, 10(10):647-656.

This list was generated on Mon Jun 17 10:49:47 2019 CEST.